ADAM metallopeptidase domain 22Genealiases: ADAM 22 · DEE61 · EIEE61 · MDC2
Q-omics provides the consensus-scored ADAM22 profile across patient tissues and cancer cell-line models. ADAM22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADAM22 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ADAM22 protein abundance shows 24,586 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where ADAM22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM22 survival associations across molecular data types. ADAM22 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM22 RNA expression–survival associations across cancer types. High ADAM22 expression shows unfavorable associations in KIRP, UVM and MESO, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADAM22 RNA expression.
This table summarizes ADAM22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ADAM22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM22 shows lower tumor expression in THCA, UCEC, BRCA and KICH and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher ADAM22 RNA expression in normal versus tumor tissue (log2 FC = −2.302, t-test p < 0.001).
This table shows molecular features associated with ADAM22 in patient tissues and cancer cell lines. In patient samples, ADAM22 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
